Mar 09, 2021 / 12:00PM GMT
Andrew S. Fein - H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst
Good morning, everyone. My name is Andrew Fein. I'm one of the biotechnology analysts with H.C. Wainwright. It's my pleasure to host a fireside chat this morning with ProQR Therapeutics. Joining from the company is Smital Shah, Chief Business Officer; as well as the Chief Financial Officer of the company. So thank you, Smital, very much for joining us.
Smital Shah - ProQR Therapeutics N.V. - Chief Business & Financial Officer
Thank you, Andrew, and thank you, H.C. Wainwright for hosting us.
Questions and Answers:
Andrew S. Fein - H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare AnalystOur pleasure. So maybe the best place to begin in light of upcoming catalysts is with 421a. You guys recently held a KOL event that I thought was very, very useful. So maybe you can begin by overviewing the program and just kind of laying out what folks ought
Trustpilot
